Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Endocrine 1

Conditions

Recurrence 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1Multiple Myeloma 1Multiple Endocrine Neoplasia Type 2a 1Lethal Congenital Contracture Syndrome 2 1Diabetes Mellitus, Insulin-Dependent, 12 1Carcinoma, Non-Small-Cell Lung 1

Interventions

pembrolizumab 119Cisplatin 33lenvatinib 29Carboplatin 28Paclitaxel 27Docetaxel 14Pemetrexed 13Fluorouracil 12Capecitabine 11Saline Solution 10Oxaliplatin 10Gemcitabine 10Albumin-Bound Paclitaxel 7olaparib 6Leucovorin 6Bevacizumab 6epacadostat 5belzutifan 5Etoposide 5Cetuximab 5130-nm albumin-bound paclitaxel 5trifluridine tipiracil drug combination 3regorafenib 3patritumab deruxtecan 3enzalutamide 3enfortumab vedotin 3durvalumab 3Surgical Procedures, Operative 3Radiotherapy 3Levoleucovorin 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Parkinson Disease 4, Autosomal Dominant Lewy Body × Antibodies, Bispecific × 1 year × Clear all
NCT05142189 2026-04-14

LuCa-MERIT-1

BioNTech SE

Phase 1 Recruiting
320 enrolled
EndocrineThoracic

Diabetes Mellitus, Insulin-Dependent, 12, Lethal Congenital Contracture Syndrome 2, Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Multiple Endocrine Neoplasia Type 2a

Data powered by HemOnc (CC BY 4.0) Colophon âš¡